Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine

Alexander E. Platonov; Irina V. Vershinina; Edward J. Kuijper; Ray Borrow; Helena Käyhty

doi:10.1016/S0264-410X(03)00440-7

Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine

Alexander E. Platonov^*
, Irina V. Vershinina
, Edward J. Kuijper
, Ray Borrow
, Helena Käyhty

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

65 Citations (Scopus)

Abstract

Of 45 Russian patients with late complement component deficiency (LCCD) who experienced one to five meningococcal infections, 31 were immunised with a meningococcal A/C/W135/Y polysaccharide vaccine and were followed for 3-8 years. Total and immunoglobulin (Ig) class specific concentration of antibodies to meningococcal polysaccharides in sera of LCCD patients increased significantly 1 month after vaccination and remained elevated for 3 years. Revaccination of LCCD patients 3 years after the first dose restored the total Ig concentrations to those observed 1 year after the first vaccination. Six new episodes of meningococcal infection in four patients developed in the group of 31 vaccinees; six episodes in six patients developed in the same time in the group of 14 non-vaccinated LCCD persons. Survival analysis demonstrated the risk to contract meningococcal disease decreased significantly for vaccinees in comparison to non-vaccinees (P<0.05). Vaccination with of meningococcal tetravalent polysaccharide vaccine decreases the risk of meningococcal infection in LCCD patients.

Original language	English
Pages (from-to)	4437-4447
Number of pages	11
Journal	Vaccine
Volume	21
Issue number	27-30
DOIs	https://doi.org/10.1016/S0264-410X(03)00440-7
Publication status	Published - 1 Oct 2003
Externally published	Yes

Bibliographical note

Funding Information:
We thank National Public Health Institute, Finland, and SmithKline Beecham Biologicals, Belgium, for the donation of capsular polysaccharide vaccine. We are thankful for Dr. Cees Fijen, Dr. Ann Orren, Professor Peter Densen, Professor Anders Sjoholm for helpful and inspiring discussions of this project, for Mrs. Sirkka-Liisa Wahlman, Mrs. Kaisa Jousimies, Mrs. Ludmila Kulagina, Mrs. Valentina Ivanova, Mrs. Galina Kovtun and Linda Mahkonen, MD for skilful technical assistance. This study was supported in a part by the grants from the International Association for the Promotion of Cooperation with Scientists from the Independent States of the Former Soviet Union (INTAS), contracts 1010-CT93-0011 and INTAS-OPEN-97–108, and by NATO linkage grant number 975119.

Keywords

Complement deficiency
Efficacy
Meningococcal vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0264-410X(03)00440-7

Cite this

@article{cd90afb9b5d449b58dc750479ea504e1,

title = "Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine",

abstract = "Of 45 Russian patients with late complement component deficiency (LCCD) who experienced one to five meningococcal infections, 31 were immunised with a meningococcal A/C/W135/Y polysaccharide vaccine and were followed for 3-8 years. Total and immunoglobulin (Ig) class specific concentration of antibodies to meningococcal polysaccharides in sera of LCCD patients increased significantly 1 month after vaccination and remained elevated for 3 years. Revaccination of LCCD patients 3 years after the first dose restored the total Ig concentrations to those observed 1 year after the first vaccination. Six new episodes of meningococcal infection in four patients developed in the group of 31 vaccinees; six episodes in six patients developed in the same time in the group of 14 non-vaccinated LCCD persons. Survival analysis demonstrated the risk to contract meningococcal disease decreased significantly for vaccinees in comparison to non-vaccinees (P<0.05). Vaccination with of meningococcal tetravalent polysaccharide vaccine decreases the risk of meningococcal infection in LCCD patients.",

keywords = "Complement deficiency, Efficacy, Meningococcal vaccine",

author = "Platonov, \{Alexander E.\} and Vershinina, \{Irina V.\} and Kuijper, \{Edward J.\} and Ray Borrow and Helena K{\"a}yhty",

note = "Funding Information: We thank National Public Health Institute, Finland, and SmithKline Beecham Biologicals, Belgium, for the donation of capsular polysaccharide vaccine. We are thankful for Dr. Cees Fijen, Dr. Ann Orren, Professor Peter Densen, Professor Anders Sjoholm for helpful and inspiring discussions of this project, for Mrs. Sirkka-Liisa Wahlman, Mrs. Kaisa Jousimies, Mrs. Ludmila Kulagina, Mrs. Valentina Ivanova, Mrs. Galina Kovtun and Linda Mahkonen, MD for skilful technical assistance. This study was supported in a part by the grants from the International Association for the Promotion of Cooperation with Scientists from the Independent States of the Former Soviet Union (INTAS), contracts 1010-CT93-0011 and INTAS-OPEN-97–108, and by NATO linkage grant number 975119. ",

year = "2003",

month = oct,

day = "1",

doi = "10.1016/S0264-410X(03)00440-7",

language = "English",

volume = "21",

pages = "4437--4447",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "27-30",

}

TY - JOUR

T1 - Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine

AU - Platonov, Alexander E.

AU - Vershinina, Irina V.

AU - Kuijper, Edward J.

AU - Borrow, Ray

AU - Käyhty, Helena

N1 - Funding Information: We thank National Public Health Institute, Finland, and SmithKline Beecham Biologicals, Belgium, for the donation of capsular polysaccharide vaccine. We are thankful for Dr. Cees Fijen, Dr. Ann Orren, Professor Peter Densen, Professor Anders Sjoholm for helpful and inspiring discussions of this project, for Mrs. Sirkka-Liisa Wahlman, Mrs. Kaisa Jousimies, Mrs. Ludmila Kulagina, Mrs. Valentina Ivanova, Mrs. Galina Kovtun and Linda Mahkonen, MD for skilful technical assistance. This study was supported in a part by the grants from the International Association for the Promotion of Cooperation with Scientists from the Independent States of the Former Soviet Union (INTAS), contracts 1010-CT93-0011 and INTAS-OPEN-97–108, and by NATO linkage grant number 975119.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Of 45 Russian patients with late complement component deficiency (LCCD) who experienced one to five meningococcal infections, 31 were immunised with a meningococcal A/C/W135/Y polysaccharide vaccine and were followed for 3-8 years. Total and immunoglobulin (Ig) class specific concentration of antibodies to meningococcal polysaccharides in sera of LCCD patients increased significantly 1 month after vaccination and remained elevated for 3 years. Revaccination of LCCD patients 3 years after the first dose restored the total Ig concentrations to those observed 1 year after the first vaccination. Six new episodes of meningococcal infection in four patients developed in the group of 31 vaccinees; six episodes in six patients developed in the same time in the group of 14 non-vaccinated LCCD persons. Survival analysis demonstrated the risk to contract meningococcal disease decreased significantly for vaccinees in comparison to non-vaccinees (P<0.05). Vaccination with of meningococcal tetravalent polysaccharide vaccine decreases the risk of meningococcal infection in LCCD patients.

AB - Of 45 Russian patients with late complement component deficiency (LCCD) who experienced one to five meningococcal infections, 31 were immunised with a meningococcal A/C/W135/Y polysaccharide vaccine and were followed for 3-8 years. Total and immunoglobulin (Ig) class specific concentration of antibodies to meningococcal polysaccharides in sera of LCCD patients increased significantly 1 month after vaccination and remained elevated for 3 years. Revaccination of LCCD patients 3 years after the first dose restored the total Ig concentrations to those observed 1 year after the first vaccination. Six new episodes of meningococcal infection in four patients developed in the group of 31 vaccinees; six episodes in six patients developed in the same time in the group of 14 non-vaccinated LCCD persons. Survival analysis demonstrated the risk to contract meningococcal disease decreased significantly for vaccinees in comparison to non-vaccinees (P<0.05). Vaccination with of meningococcal tetravalent polysaccharide vaccine decreases the risk of meningococcal infection in LCCD patients.

KW - Complement deficiency

KW - Efficacy

KW - Meningococcal vaccine

UR - https://www.scopus.com/pages/publications/0348078307

U2 - 10.1016/S0264-410X(03)00440-7

DO - 10.1016/S0264-410X(03)00440-7

M3 - Article

C2 - 14505927

AN - SCOPUS:0348078307

SN - 0264-410X

VL - 21

SP - 4437

EP - 4447

JO - Vaccine

JF - Vaccine

IS - 27-30

ER -

Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this